BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?

Opinion statement The BRAF activating mutation, harbored by approximately 10% of colorectal cancers (CRC), confers dramatic prognosis to advanced diseases. In early-stage setting, the identification of the BRAF mutation does not impact the therapeutic decision. Yet, the BRAF mutation could be consid...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current treatment options in oncology 2017-02, Vol.18 (2), p.9-9, Article 9
Hauptverfasser:	Cohen, Romain, Cervera, Pascale, Svrcek, Magali, Pellat, Anna, Dreyer, Chantal, de Gramont, Aimery, André, Thierry
Format:	Artikel
Sprache:	eng
Schlagworte:	5-Fluorouracil Amino Acid Substitution Antiangiogenic agents Bevacizumab Chemotherapy Clinical trials Codon Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - diagnosis Colorectal Neoplasms - genetics Colorectal Neoplasms - therapy Combined Modality Therapy Cytotoxicity DNA Mismatch Repair - drug effects Epidermal growth factor receptors Genetic disorders Genetic Predisposition to Disease Humans Immune checkpoint inhibitors Irinotecan Lower Gastrointestinal Cancers (AB Benson MAP kinase Medical innovations Medicine Medicine & Public Health Microsatellite Instability Mismatch repair MLH1 protein Molecular Targeted Therapy Monoclonal antibodies Mutation Neoplasm Metastasis Neoplasm Staging Oncology Oxaliplatin Prognosis Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics Section Editor Targeted cancer therapy Topical Collection on Lower Gastrointestinal Cancers Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!